Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 11/20 | 0.67 |
| ▸ | RAF1 | P04049 | 5/20 | 0.61 |
| ▸ | EGFR | P00533 | 7/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.59 |
| ▸ | STK4 | Q13043 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5253113 | 0.90 | MAP2K1 (0.82) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL676613 | 0.82 | MAP2K1 (0.78) | MAP2K1RAF1EGFRERBB2STK4 | |
| SCHEMBL29556194 | 0.82 | MAP2K1 (0.78) | MAP2K1RAF1EGFRERBB2STK4 | |
| SCHEMBL5252936 | 0.82 | EGFR (0.76) | EGFRERBB2 | |
| SCHEMBL28756490 | 0.82 | MAP2K1 (0.95) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL4775833 | 0.81 | MAP2K1 (0.60) | MAP2K1RAF1EGFRERBB2STK4 | |
| SCHEMBL6111492 | 0.81 | MAP2K1 (0.67) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL21341769 | 0.81 | MAP2K1 (0.67) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL3468320 | 0.81 | MAP2K1 (0.60) | MAP2K1RAF1EGFRERBB2STK4 | |
| SCHEMBL5251276 | 0.81 | MAP2K1 (1.00) | MAP2K1RAF1EGFRERBB2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171874-A1 | METHOD FOR THE REGIOSELECTIVE PREPARATION OF SUBSTITUTED BENZO[G]QUINOLINE-3-CARBONITRILES AND BENZO[G]QUINAZOLINES | WYETH (US) | 2008-07-17 | — | — | US | disclosed |
| US-7365197-B2 | Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| US-20060041127-A1 | Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines | WYETH | 2006-02-23 | — | — | US | disclosed |
| EP-1345889-A1 | METHOD FOR THE REGIOSELECTIVE PREPARATION OF SUBSTITUTED BENZO G]QUINOLINE-3-CARBONITRILES AND BENZO G]QUINAZOLINES | Wyeth (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20020091273-A1 | Method for the regioselective preparation of substituted benzo[g]quinoline3-carbonitriles and benzo[g]quinazolines | AMERICAN HOME PRODUCTS CORPORATION | 2002-07-11 | — | — | US | disclosed |
| WO-2002053528-A1 | METHOD FOR THE REGIOSELECTIVE PREPARATION OF SUBSTITUTED BENZO[G]QUINOLINE-3-CARBONITRILES AND BENZO[G]QUINAZOLINES | WYETH (US) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171874-A1 | METHOD FOR THE REGIOSELECTIVE PREPARATION OF SUBSTITUTED BENZO[G]QUINOLINE-3-CARBONITRILES AND BENZO[G]QUINAZOLINES | PDXK, PKD1, GLS | MAP2K1 834/4885RAF1 243/4885EGFR 1517/4885 |
| US-20060041127-A1 | Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines | PDXK, PKD1, GLS | MAP2K1 834/4885RAF1 243/4885EGFR 1517/4885 |
| US-20020091273-A1 | Method for the regioselective preparation of substituted benzo[g]quinoline3-carbonitriles and benzo[g]quinazolines | PDXK, PKD1, PFKP | MAP2K1 806/4885RAF1 309/4885EGFR 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.